These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

500 related items for PubMed ID: 17164229

  • 1. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases.
    Veronesi U, De Cicco C, Galimberti VE, Fernandez JR, Rotmensz N, Viale G, Spano G, Luini A, Intra M, Veronesi P, Berrettini A, Paganelli G.
    Ann Oncol; 2007 Mar; 18(3):473-8. PubMed ID: 17164229
    [Abstract] [Full Text] [Related]

  • 2. Selective Sentinel Node Plus Additional Non-Sentinel Node Biopsy Based on an FDG-PET/CT Scan in Early Breast Cancer Patients: Single Institutional Experience.
    Kim J, Lee J, Chang E, Kim S, Suh K, Sul J, Song I, Kim Y, Lee C.
    World J Surg; 2009 May; 33(5):943-9. PubMed ID: 19259728
    [Abstract] [Full Text] [Related]

  • 3. Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer.
    van der Hoeven JJ, Hoekstra OS, Comans EF, Pijpers R, Boom RP, van Geldere D, Meijer S, Lammertsma AA, Teule GJ.
    Ann Surg; 2002 Nov; 236(5):619-24. PubMed ID: 12409668
    [Abstract] [Full Text] [Related]

  • 4. FDG-PET for axillary lymph node staging in primary breast cancer.
    Crippa F, Gerali A, Alessi A, Agresti R, Bombardieri E.
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S97-102. PubMed ID: 15133635
    [Abstract] [Full Text] [Related]

  • 5. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management.
    Greco M, Crippa F, Agresti R, Seregni E, Gerali A, Giovanazzi R, Micheli A, Asero S, Ferraris C, Gennaro M, Bombardieri E, Cascinelli N.
    J Natl Cancer Inst; 2001 Apr 18; 93(8):630-5. PubMed ID: 11309439
    [Abstract] [Full Text] [Related]

  • 6. Prospective study of 2-[¹⁸F]fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer: an Ontario clinical oncology group study.
    Pritchard KI, Julian JA, Holloway CM, McCready D, Gulenchyn KY, George R, Hodgson N, Lovrics P, Perera F, Elavathil L, O'Malley FP, Down N, Bodurtha A, Shelley W, Levine MN.
    J Clin Oncol; 2012 Apr 20; 30(12):1274-9. PubMed ID: 22393089
    [Abstract] [Full Text] [Related]

  • 7. Determination of indication for sentinel lymph node biopsy in clinical node-negative breast cancer using preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging.
    Taira N, Ohsumi S, Takabatake D, Hara F, Takashima S, Aogi K, Takashima S, Inoue T, Sugata S, Nishimura R.
    Jpn J Clin Oncol; 2009 Jan 20; 39(1):16-21. PubMed ID: 18997183
    [Abstract] [Full Text] [Related]

  • 8. Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy.
    Ergul N, Kadioglu H, Yildiz S, Yucel SB, Gucin Z, Erdogan EB, Aydin M, Muslumanoglu M.
    Acta Radiol; 2015 Aug 20; 56(8):917-23. PubMed ID: 25013091
    [Abstract] [Full Text] [Related]

  • 9. Prediction of Extracapsular Invasion at Metastatic Sentinel Nodes and Non-sentinel Lymph Nodal Metastases by FDG-PET in Cases with Breast Cancer.
    Fujii T, Yajima R, Tatsuki H, Kuwano H.
    Anticancer Res; 2016 Apr 20; 36(4):1785-9. PubMed ID: 27069160
    [Abstract] [Full Text] [Related]

  • 10. Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer.
    Ueda S, Tsuda H, Asakawa H, Omata J, Fukatsu K, Kondo N, Kondo T, Hama Y, Tamura K, Ishida J, Abe Y, Mochizuki H.
    BMC Cancer; 2008 Jun 09; 8():165. PubMed ID: 18541009
    [Abstract] [Full Text] [Related]

  • 11. Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer.
    Gil-Rendo A, Zornoza G, García-Velloso MJ, Regueira FM, Beorlegui C, Cervera M.
    Br J Surg; 2006 Jun 09; 93(6):707-12. PubMed ID: 16622900
    [Abstract] [Full Text] [Related]

  • 12. Factors affecting the accuracy of 18F-FDG PET/CT in evaluating axillary metastases in invasive breast cancer.
    Kutluturk K, Simsek A, Comak A, Gonultas F, Unal B, Kekilli E.
    Niger J Clin Pract; 2019 Jan 09; 22(1):63-68. PubMed ID: 30666022
    [Abstract] [Full Text] [Related]

  • 13. Different biological and prognostic breast cancer populations identified by FDG-PET in sentinel node-positive patients: results and clinical implications after eight-years follow-up.
    Agresti R, Crippa F, Sandri M, Martelli G, Tagliabue E, Alessi A, Pellitteri C, Maccauro M, Maugeri I, Barbara P, Rampa M, Moscaroli A, Ferraris C, Carcangiu ML, Bianchi G, Greco M, Bombardieri E.
    Breast; 2014 Aug 09; 23(4):334-40. PubMed ID: 24485802
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the diagnostic value of FDG-PET/CT and axillary ultrasound for the detection of lymph node metastases in breast cancer patients.
    Riegger C, Koeninger A, Hartung V, Otterbach F, Kimmig R, Forsting M, Bockisch A, Antoch G, Heusner TA.
    Acta Radiol; 2012 Dec 01; 53(10):1092-8. PubMed ID: 23002144
    [Abstract] [Full Text] [Related]

  • 15. Investigation of 18F-FDG PET in the selection of patients with breast cancer as candidates for sentinel node biopsy after neoadjuvant therapy.
    Gilardi L, De Cicco C, Colleoni M, Cardillo A, Montagna E, Dellapasqua S, Galimberti V, Bagnardi V, Paganelli G.
    Eur J Nucl Med Mol Imaging; 2010 Oct 01; 37(10):1834-41. PubMed ID: 20533032
    [Abstract] [Full Text] [Related]

  • 16. Axillary staging using positron emission tomography in breast cancer patients qualifying for sentinel lymph node biopsy.
    Fehr MK, Hornung R, Varga Z, Burger D, Hess T, Haller U, Fink D, von Schulthess GK, Steinert HC.
    Breast J; 2004 Oct 01; 10(2):89-93. PubMed ID: 15009033
    [Abstract] [Full Text] [Related]

  • 17. Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients.
    Heusner TA, Kuemmel S, Hahn S, Koeninger A, Otterbach F, Hamami ME, Kimmig KR, Forsting M, Bockisch A, Antoch G, Stahl A.
    Eur J Nucl Med Mol Imaging; 2009 Oct 01; 36(10):1543-50. PubMed ID: 19415270
    [Abstract] [Full Text] [Related]

  • 18. Sentinel node biopsy versus low axillary sampling in women with clinically node negative operable breast cancer.
    Parmar V, Hawaldar R, Nair NS, Shet T, Vanmali V, Desai S, Gupta S, Rangrajan V, Mittra I, Badwe RA.
    Breast; 2013 Dec 01; 22(6):1081-6. PubMed ID: 23948301
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of fluorodeoxyglucose positron emission tomography in the detection of axillary lymph node metastases in patients with early-stage breast cancer.
    Barranger E, Grahek D, Antoine M, Montravers F, Talbot JN, Uzan S.
    Ann Surg Oncol; 2003 Jul 01; 10(6):622-7. PubMed ID: 12839846
    [Abstract] [Full Text] [Related]

  • 20. FDG PET positive lymph nodes are highly predictive of metastasis in breast cancer.
    Kumar R, Zhuang H, Schnall M, Conant E, Damia S, Weinstein S, Chandra P, Czerniecki B, Alavi A.
    Nucl Med Commun; 2006 Mar 01; 27(3):231-6. PubMed ID: 16479242
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.